Interestingly, we found genomic aberrations in LUZP1 at high frequency in cancer specimens, reaching an alteration frequency of almost 80% in cholangiocarcinoma and greater than 40% in 13 out of the 54 cancer types that we analyzed (Figure 1A). Here, LUZP1 is linked to cholangiocarcinoma.